APPENDICES
APPENDICES
Appendix 1 Further details on Methods
Search strategy
For journal articles, the search in PubMed (incorporating MEDLINE) was performed using the MeSH subheading “digestive system neoplasms”. This included: biliary tract neoplasms (bile duct neoplasms and gallbladder neoplasms), gastrointestinal neoplasms (oesophageal neoplasms, intestinal neoplasms [caecal, colorectal, duodenal, jejunal, ileal], stomach neoplasms, and gastrointestinal stromal tumours), liver neoplasms, pancreatic neoplasm and peritoneal neoplasms. Gastrointestinal stromal neoplams and peritoneal neoplams were excluded. This search term was combined with “randomized OR randomised controlled trials*” and ‘(phase 3 OR phase III)’, and limited the search to trials in humans, in English language, and published from 01/01/2003 to 01/08/2012, with 463 potential articles identified.
Data extraction
For journal articles, the title and abstract (and additionally full text if the former was unclear) of each article citation identified by literature search was screened and eligibility was determined. For conference abstracts, the title and abstract were screened and eligibility was determined. For conference abstracts initially published as a late breaking abstract, the most current version available was used. Information from two or more articles reporting results from the same trial, and information from two or more conference proceedings abstracts reporting results from the same trial were amalgamated.
Data was entered into validated Microsoft Excel spreadsheets, and extracted as follows. The primary endpoint was documented. If there were co-primary endpoints, then the endpoint that the predominant statistical analysis was based on was selected as the primary endpoint. Where it was not clear what the primary endpoint was, then trial registration websites were searched, and for conference proceeding abstracts, journal articles reporting the study were checked where available. Where it was not possible to discriminate, then the total number of subgroup analyses for co-primary endpoints were recorded as the primary endpoint.
Appendix 2 PRISMA flow diagram for journal article
PRISMA flow diagram for conference abstracts
Appendix 3
Journal article references
Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM (2006) Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24: 4441-4447
Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS (2011) Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12: 642-653
Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28: 1547-1553
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, III, Thomas CR, Jr., Mayer RJ, Haddock MG, Rich TA, Willett C (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299: 1914-1921
Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jager E (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26: 1435-1442
Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH, Jr., Pockaj BA, Grothey A, Goldberg RM (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307: 1383-1393
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N (2011) Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29: 11-16
Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de GA (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351
Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de GA (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109-3116
Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de GA (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21: 2896-2903
Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de GA (2007) Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 25: 3732-3738
Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29: 2773-2780
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzen F, Noh SH (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379: 315-321
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697
Barbare JC, Bouche O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L (2009) Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer 45: 1788-1797
Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Herrmann R (2008) Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 26: 3695-3701
Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10: 1063-1069
Bouche O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P (2005) Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 16: 1488-1497
Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Pahlman L, Wiig JN, Bystrom P, Bujko K, Glimelius B (2008) Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26: 3687-3694
Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW (2005) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6: 659-668
Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I, Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A (2007) Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 99: 601-607
Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26: 2006-2012
Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105: 58-64
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34
Chipponi J, Huguier M, Pezet D, Basso N, Hay JM, Quandalle P, Jaeck D, Fagniez PL, Gainant A (2004) Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 187: 440-445
Chong G, Bhatnagar A, Cunningham D, Cosgriff TM, Harper PG, Steward W, Bridgewater J, Moore M, Cassidy J, Coleman R, Coxon F, Redfern CH, Jones JJ, Hawkins R, Northfelt D, Sreedharan S, Valone F, Carmichael J (2006) Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol 17: 437-442
Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, Tidmarsh GT (2009) A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer 45: 1589-1596
Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di SM, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di BM, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875
Colucci G, Labianca R, Di CF, Gebbia V, Carteni G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolo M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di MM, Perrone F (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28: 1645-1651
Comella P, Massidda B, Filippelli G, Palmeri S, Natale D, Farris A, De VF, Buzzi F, Tafuto S, Maiorino L, Mancarella S, Leo S, Lorusso V, De LL, Roselli M (2005) Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 16: 878-886
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC TP (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP (2009a) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345
Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, Koralewski P, Bridgewater J, Mainwaring P, Wasan H, Wang JY, Szczylik C, Clingan P, Chan RT, Tabah-Fisch I, Cassidy J (2009b) Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 20: 244-250
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46
Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL, Rougier P, Bedenne L, Seitz JF (2010) Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 59: 1527-1534
Dahl O, Fluge O, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM (2009) Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol 48: 368-376
Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19: 1450-1457
de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, Andre T, Hoff PM (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13: 1225-1233
De Placido S, Lopez M, Carlomagno C, Paoletti G, Palazzo S, Manzione L, Iannace C, Ianniello GP, De VF, Ficorella C, Farris A, Pistillucci G, Gemini M, Cortesi E, Adamo V, Gebbia N, Palmeri S, Gallo C, Perrone F, Persico G, Bianco AR (2005) Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. Br J Cancer 93: 896-904
De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di MN, Montemurro F, Carteni G, Manzione L, Romito S, Gebbia V, Ciardiello F, Catalano G, Colucci G (2007) Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 18: 1354-1358
Di Bartolomeo M, Buzzoni R, Mariani L, Ferrario E, Katia D, Gevorgyan A, Zilembo N, Bordonaro R, Bochicchio AM, Massidda B, Ardizzoia A, Marini G, Aitini E, Schieppati G, Comella G, Pinotti G, Palazzo S, Cicero G, Bajetta E, Villa E, Fagnani D, Reguzzoni G, Agostana B, Oliani C, Kildani B, Duro M, Botta M, Mozzana R, Mantovani G (2006) Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. Oncology 71: 341-346
Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio CB, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De SM, Dalla MA, Camera S, Recchia F, De FS, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani LA, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di CF, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R (2008) Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 100: 388-398
Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martinez de PP, Gallen M, Gonzalez E, Marcuello E, Benavides M, Fernandez-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Duenas R, Lopez-Ladron A, Lacasta A, Llanos M, Tabernero JM, Anton A, Aranda E (2012) First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 17: 15-25
Diaz-Rubio E, Tabernero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, Gonzalez-Flores E, Aparicio J, Rivera F, Losa F, Aranda E (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25: 4224-4230
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705
Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, Rougier P, Gasmi M, Castaing M, Abbas M, Michel P, Gargot D, Azzedine A, Lombard-Bohas C, Geoffroy P, Denis B, Pignon JP, Bedenne L, Bouche O (2011) Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 12: 1032-1044
Duffour J, Bouche O, Rougier P, Milan C, Bedenne L, Seitz JF, Buecher B, Legoux JL, Ducreux M, Vetter D, Raoul JL, Francois E, Ychou M (2006) Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Res 26: 3877-3883
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676
Fields AL, Keller A, Schwartzberg L, Bernard S, Kardinal C, Cohen A, Schulz J, Eisenberg P, Forster J, Wissel P (2009) Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 27: 1941-1947
Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambertz H, Oruzio D, Schlag R, Weigang-Kohler K, Vehling-Kaiser U, Schulze M, Truckenbrodt J, Goebeler M, Mittermuller J, Bosse D, Szukics B, Grundeis M, Zwingers T, Giessen C, Heinemann V (2011) Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 47: 206-214
Fuchs CS, Marshall J, Barrueco J (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26: 689-690
Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21: 807-814
Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26: 2099-2105
Gennatas C, Papaxoinis G, Michalaki V, Mouratidou D, Andreadis C, Tsavaris N, Pafiti A (2006) A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. J Chemother 18: 538-544
Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Francois E, de La RG, Bouche O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahe MA, Becouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28: 1638-1644
Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo RG, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Levi F (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24: 3562-3569
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB, III (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544
Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT (2007) Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25: 3069-3075
Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit K, Heikkila R, Keldsen N, Albertsson M, Starkhammar H, Garmo H, Berglund A (2008) A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 19: 909-914
Gray R, Barnwell J, McConkey C, Hills RK, WILLIAMS NS, Kerr DJ (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370: 2020-2029
Haller DG, Catalano PJ, Macdonald JS, O'rourke MA, Frontiera MS, Jackson DV, Mayer RJ (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23: 8671-8678
Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH, Jr., Bodoky G, Habboubi N, Garay C, Olivatto LO (2008) Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 26: 4544-4550
Haller DG, Tabernero J, Maroun J, de BF, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29: 1465-1471
Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672-680
Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D (2011) Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29: 1997-2003
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952
Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25: 2212-2217
Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Muller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13: 579-588
Hospers GA, Schaapveld M, Nortier JW, Wils J, van BA, de Jong RS, Creemers GJ, Erjavec Z, de Gooyer DJ, Slee PH, Gerrits CJ, Smit JM, Mulder NH (2006) Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. Ann Oncol 17: 443-449
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
James RD, Donaldson D, Gray R, Northover JM, Stenning SP, Taylor I (2003) Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS). Br J Surg 90: 1200-1212
Jeung HC, Moon YW, Rha SY, Yoo NC, Roh JK, Noh SH, Min JS, Kim BS, Chung HC (2008) Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol 19: 520-526
Jonker DJ, O'callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van HG, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048
Kalofonos HP, Bamias A, Koutras A, Papakostas P, Basdanis G, Samantas E, Karina M, Misailidou D, Pisanidis N, Pentheroudakis G, Economopoulos T, Papadimitriou C, Skarlos DV, Pectasides D, Stavropoulos M, Bafaloukos D, Kardamakis D, Karanikiotis C, Vourli G, Fountzilas G (2008) A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer 44: 1693-1700
Kang JH, Lee SI, Lim dH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30: 1513-1518
Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20: 666-673
Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Jr., Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC (2009) Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 27: 2848-2854
Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E (2011) Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12: 256-262
Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622
Kohne CH, Van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Ruckle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Muller L, Genicot B, Anak O, Nordlinger B (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23: 4856-4865
Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ (2003) Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 21: 3721-3728
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van BA, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370: 135-142
Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47: 2117-2127
Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25: 2198-2204
Kulig J, Kolodziejczyk P, Sierzega M, Bobrzynski L, Jedrys J, Popiela T, Dadan J, Drews M, Jeziorski A, Krawczyk M, Starzynska T, Wallner G (2010) Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology 78: 54-61
Lal R, Dickson J, Cunningham D, Chau I, Norman AR, Ross PJ, Topham C, Middleton G, Hill M, Oates J (2004) A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol 22: 3023-3031
Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK, Lim HY (2012) Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13: 181-188
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de GA (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103-2114
Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ (2003) Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361: 457-464
Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, Julier P, Iveson C, Yanagisawa Y, Warren B, Langman MJ, Kerr DJ (2010) Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 28: 4575-4580
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966
Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21: 3296-3302
Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11: 853-860
Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y (2011) Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 14: 72-80
Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Olah A, Rawcliffe CL, Verbeke CS, Campbell F, Buchler MW (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308: 147-156
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304: 1073-1081
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210
Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz JF, Guimares dos SJ, Bleiberg H, Mackiewickz R, Conroy T, Bouche O, Morin T, Baila L, Van Cutsem E, Bedenne L (2005) Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol 6: 459-468
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007-1016
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277
Oettle H, Richards D, Ramanathan RK, Van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von HD, Arning M, Kindler HL (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16: 1639-1645
Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29: 3968-3976
Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21: 54-59
Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G, Xiros N, Klouvas G, Bafaloukos D, Kafiri G, Papaspirou I, Pectasides D, Karanikiotis C, Economopoulos T, Efstratiou I, Korantzis I, Pisanidis N, Makatsoris T, Matsiakou F, Aravantinos G, Kalofonos HP, Fountzilas G (2011) A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med 9: 10
Park JH, Yoon SM, Yu CS, Kim JH, Kim TW, Kim JC (2011) Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer 117: 3703-3712
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706-4713
Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28: 3605-3610
Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB, III (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27: 3778-3785
Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS (2005) Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23: 1819-1825
Popov I, Carrato A, Sobrero A, Vincent M, Kerr D, Labianca R, Raffaele BA, El-Serafi M, Bedenne L, Paillot B, Mini E, Sanches E, Welch J, Collette L, Praet M, Wils J (2008) Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer 44: 2204-2211
Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223
Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D (2004) Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer 3: 235-242
Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S (2002) Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 360: 671-677
Rao S, Cunningham D, de GA, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Park YC, Palmer PA (2004) Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22: 3950-3957
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501-513
Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG (2011) Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 18: 1319-1326
Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA (2008) Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299: 1019-1026
Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S, Siu LL, Laguerre S, Cunningham D (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19: 1720-1726
Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le BN, Haller DG (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820
Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker WG, Birchfield G, Tokaz LK, Barrera D, Conkling PR, O'rourke MA, Richards DA, Reidy D, Solit D, Vakiani E, Capanu M, Scales A, Zhan F, Boehm KA, Asmar L, Cohn A (2012) Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer 11: 101-111
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008a) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019
Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29: 4387-4393
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rodel C (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30: 1926-1933
Schippinger W, Jagoditsch M, Sorre C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger HJ, Hofbauer F, Holzberger P, Mittlbock M, Jakesz R (2005) A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br J Cancer 92: 1655-1662
Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thodtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J (2007) A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 97: 1021-1027
Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370: 143-152
Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377: 1749-1759
Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB, III, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS, Jr., Leichman CG, Macdonald JS (2006) Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 24: 3542-3547
Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kroning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA, III (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319
Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis C, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94: 798-805
Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ (2010) Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28: 3191-3198
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de GA (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237
Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012) Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 30: 1755-1762
Twelves C, Scheithauer W, McKendrick J, Seitz JF, van HG, Wong A, Diaz-Rubio E, Gilberg F, Cassidy J (2012) Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 23: 1190-1197
Twelves C, Wong A, Nowacki MP, Abt M, Burris H, III, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, van HG, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352: 2696-2704
Uyl-de Groot CA, Vermorken JB, Hanna MG, Jr., Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM (2005) Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23: 2379-2387
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281
Van Cutsem E, Bajetta E, Valle J, Kohne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lebwohl D, Meinhardt G, Laurent D, Lin E (2011a) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29: 2004-2010
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009a) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417
Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011b) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019
Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, Andre T, Sobrero AF, Mini E, Greil R, Di CF, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D (2009b) Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27: 3117-3125
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664
Van CutsemE, van d, V, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez RJ, Ma Y, Von Hoff D (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22: 1430-1438
Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ (2009c) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27: 2231-2237
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van DH, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366: 2074-2084
Vermorken JB, Claessen AM, van TH, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG, Jr., Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353: 345-350
Wils J, Blijham GH, Wagener T, De GJ, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B (2003) High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer 39: 346-352
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523
Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29: 1715-1721
Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung CC, Santoro A (2009a) A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20: 1964-1970
Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, Viret F, Becouarn Y, Bouche O, Gamelin E, Ducreux M, Conroy T, Seitz JF, Bedenne L, Kramar A (2009b) A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20: 674-680
Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97: 1532-1538
Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29: 3768-3774
Conference abstract references
1. Ford H, Marshall A, Wadsley J, Coxon FY, Mansoor W, Bridgewater JA, et al. COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):LBA4.
2. Fuchs CS, Tomasek J, Cho JY, Dumitru F, Passalacqua R, Goswami C, et al. REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line. ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):LBA5.
3. Bang Y-J. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):11.
4. Higuchi K, Koizumi W, Yamada Y, Nishikawa K, Gotoh M, Fuse N, et al. Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer. ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):60.
5. Uesaka K, Fukutomi A, Boku N, Kanemoto H, Konishi M, Matsumoto I, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):145.
6. Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):LBA148.
7. Deplanque G, Demarchi M, Hebbar M, Flynn PJ, Melichar B, Atkins J, et al. Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial. ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):158.
8. Lombard-Bohas C, Yao JC, Hobday TJ, Van Cutsem E, Wolin EM, Panneerselvam A, et al. Efficacy and safety of everolimus in patients with advanced low- or intermediate-grade pancreatic neuroendocrine tumors previously treated with chemotherapy: RADIANT-3 subgroup analysis. ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):224.
9. Cainap C, Qin S, Huang W-T, Chung I-J, Pan H, Cheng Y, et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):249.
10. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Trenta P, et al. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. ASCO Meet. Abstr. 2013 Jan 30;31(4_suppl):336.
11. Cunningham D, Lang I, Lorusso V, Ocvirk J, Shin D, Jonker DJ, et al. Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX). ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):337.
12. Samson B, Tournigand C, Scheithauer W, Lledo G, Viret F, Andre T, et al. Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial. ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):448.
13. Mitchell EP, Guarino MJ, Allegra CJ, Boelle E, Andria ML, Bhargava P, et al. North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo (pbo) plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen. ASCO Meet. Abstr. . 2013 Jan 30;31 (4_suppl ):465.
14. Salazar R, Mini E, Folprecht G, Subtil F, van Laethem J, Thaler J, et al. ADJUVANT FOLFOX4 PLUS OR MINUS CETUXIMAB (CMAB) IN PATIENTS (PTS) WITH KRAS MUTANT (MKRAS) RESECTED STAGE III COLON CANCER (CC). RESULTS FROM THE PETACC8 INTERGROUP TRIAL. 37th Congr. Eur. Vienna, AUSTRIA: OXFORD UNIV PRESS; 2012.
15. Mitry, E. Venat-Bouvet, L. Phelip, J. Maillard, E. Jouve, J. Adhoute, X. Gargot, D. Gasmi, M. Bedenne, L. Aparicio T. RANDOMIZED PHASE III IN ELDERLY PATIENTS COMPARING LV5FU2 WITH OR WITHOUT IRINOTECAN FOR 1ST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (FFCD 2001-02). 37th Congr. Eur. Vienna, AUSTRIA: OXFORD UNIV PRESS; 2012.
16. Kondo, K. Sadahiro, S. Tsuchiya, T. Sasaki, K. Katsumata, K. Nishimura, G. Kakeji, Y. Baba, H. Kodaira, S. Saji S. PHASE III TRIAL OF TREATMENT DURATION FOR ORAL URACIL AND TEGAFUL/LEUKOVORIN ADJUVANT CHEMOTHERAPY FOR PATIENTS (PTS) WITH STAGE IIB/III COLON CANCER: RESULT OF JFMC33-0502. 37th Congr. Eur. Vienna, AUSTRIA: OXFORD UNIV PRESS; 2012.
17. Bouche, O. Steffens, C. Andre, T. Bennouna, J. Sastre, J. Osterlund, P. von Moos, R. Reyes-Rivera, I. Sersch, M. A. Arnold D. EFFICACY AND SAFETY OF TREATMENT WITH BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV plus CT: AGE SUBGROUP ANALYSIS FROM A RANDOMISED PHASE III INTER. 37th Congr. Eur. Vienna, AUSTRIA: OXFORD UNIV PRESS; 2012.
18. Vieitez de Prado JM, Borg C, Arnold D, Greil R, Van Cutsem EJD, von Moos R, et al. BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV-BASED THERAPY: OVERALL SURVIVAL SUBGROUP FINDINGS FROM ML18147. 37th Congr. Eur. Vienna, AUSTRIA: OXFORD UNIV PRESS; 2012.
19. Osterlund P, Alonso-Orduna V, Schlichting C, Andre T, Sastre J, Greil R, et al. BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH FIRST-LINE BEV plus CT (ML18147): EFFICACY AND SAFETY ANALYSES BY OXALIPLATIN VS IRINOTECAN-BASED CT. 37th Congr. Eur. Vienna, AUSTRIA: OXFORD UNIV PRESS; 2012.
20. Waddell, T. S. Reis-Filho, J. Gonzalez-De-Castro, D. Chau, I. Wotherspoon, A. Gupta, S. Saffery, C. Middleton, G. Wadsley, J. Cunningham D. A RANDOMISED MULTICENTRE TRIAL OF EPIRUBICIN, OXALIPLATIN AND CAPECITABINE (EOC) plus PANITUMUMAB IN ADVANCED OESOPHAGO-GASTRIC CANCER (REAL3): UPDATED RESULTS. ESMO. Vienna, AUSTRIA: OXFORD UNIV PRESS; 2012.
21. Ajani, J. A. Rodriguez Pantigoso, W. Bodoky, G. Moiseyenko, V. Lichinitser, M. Gorbunova, V. A. Vynnychenko, I. Lang, I. Falcon S. NON INFERIORITY ANALYSIS OF MULTICENTER PHASE III COMPARING CISPLATIN/S-1 (CS) WITH CISPLATIN/5-FU (CF) AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER (FLAGS): METHODOLOGY AND RESULTS. ESMO. Vienna, AUSTRIA: OXFORD UNIV PRESS; 2012.
22. Shen, L. Xu, R. Wang, J. Bai, Y. Liu, T. Jiao, S. Xu, J. Liu, Y. Fan N. A RANDOMIZED, CONTROLLED PHASE III TRIAL OF DOCETAXEL, CISPLATIN AND FLUOROURACIL (DCF) VERSUS CISPLATIN PLUS FLUOROURACIL (CF) AS FIRST-LINE THERAPY IN CHINESE ADVANCED GASTRIC CANCER. ESMO. Vienna, AUSTRIA: OXFORD UNIV PRESS; 2012.
23. Nishina, T. Hironaka, S. Tsuji, A. Suzuki, K. Otsuji, T. Shibata, T. Morita, S. Okamoto, I. Boku, N. Hyodo I. FINAL ANALYSIS OF RANDOMIZED PHASE III STUDY WJOG4007 COMPARING IRINOTECAN (CPT-11) WITH WEEKLY PACLITAXEL (WPTX) IN ADVANCED GASTRIC CANCER (AGC) REFRACTORY TO CHEMOTHERAPY (CT) OF FLUOROPYRIMIDINE PLUS PLATINUM (FP). ESMO. Vienna, AUSTRIA: OXFORD UNIV PRESS; 2012.
24. Waddell TS, Chau I, Barbachano Y, Gonzalez de Castro D, Wotherspoon A, Saffery C, et al. A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):LBA4000.
25. Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Landi L, Santoro A, et al. Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV reg. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):LBA4001.
26. Ueda S, Hironaka S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):4002.
27. Conroy T, Galais M-P, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard J-Y, et al. Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):LBA4003.
28. Glynne-Jones R, James R, Meadows H, Begum R, Cunningham D, Northover J, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):4004.
29. Sebag-Montefiore D, James R, Meadows H, Begum R, Cunningham D, Northover J, et al. The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):4029.
30. Haas M, Boeck SH, Laubender RP, Modest DP, Vehling-Kaiser U, Waldschmidt D, et al. Correlation of hand-foot skin reaction (HFS) with treatment efficacy in pancreatic cancer (PC) patients (pts) treated with gemcitabine/capecitabine plus erlotinib: A subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced . ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):4023.
31. Fukutomi A, Okusaka T, Sugimori K, Ueno H, Ioka T, Ohkawa S, et al. Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):4035.
32. Wild AT, Laheru D, Wang H, Chang KJ, Taylor GE, Donehower RC, et al. A randomized phase III multi-institutional study of TNFerade biologic with 5-FU and radiotherapy for locally advanced pancreatic cancer: Final results. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):4055.
33. Vinik A, Van Cutsem E, Niccoli P, Raoul J-L, Bang Y-J, Borbath I, et al. Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):4118.
34. Tournigand C, Samson B, Scheithauer W, Lledo G, Viret F, Andre T, et al. Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):LBA3500.
35. Bendell JC, Ervin TJ, Senzer NN, Richards DA, Firdaus I, Lockhart AC, et al. Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):LBA3501.
36. Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):3502.
37. Arnold D, Andre T, Bennouna J, Sastre J, Osterlund PJ, Greil R, et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):CRA3503.
38. Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, et al. Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Gro. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):3504.
39. Allegra CJ, Lakomy R, Tabernero J, Prausova J, Ruff P, Van Hazel G, et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):3505.
40. Joulain F, Van Cutsem E, Iqbal SU, Hoyle M, Allegra CJ. Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): Mean overall survival (OS) estimation from a phase III trial (VELOUR). ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):3602.
41. Hebbar M, Chibaudel B, Andre T, Mineur L, Smith D, Louvet C, et al. FOLFOX4 (12 cycles) versus sequential dose-dense FOLFOX7 (6 cycles) followed by FOLFIRI (6 cycles) in patients with initially resectable metastatic colorectal cancer: A GERCOR randomized phase III study (MIROX). ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):3506.
42. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):3508.
43. Shimada Y, Hamaguchi T, Moriya Y, Saito N, Kanemitsu Y, Takiguchi N, et al. Randomized phase III study of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients (pts) with stage III colon cancer (CC): Final results of Japan Clinical Oncology Group study (JCO. ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):3524.
44. Sobrero AF, Peeters M, Price TJ, Hotko Y, Cervantes-Ruiperez A, Ducreux M, et al. Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second-line treatment (tx) of metastatic colorectal cancer (mCRC). ASCO Meet. Abstr. . 2012 May 30;30 (15_suppl ):3535.
45. Van Cutsem, Eric Hamamoto, Yasuo Lee, Jeeyun Ohtsu, Atsushi Qin, Shukui Price, Timothy Xu, Rui-Hua Song, Eun-Kee Bi, Feng Bouche, Olivier Feliu, Alain Nesheiwat, Tonia Delaney, Rosemary Chen, Joann Costantini, Chiara Rizvi, Syed Sahmoud, Tarek Doi T. PROGNOSTIC FACTORS OF OVERALL SURVIVAL (OS) IN PREVIOUSLY TREATED ADVANCED GASTRIC CANCER (AGC): ANALYSIS OF THE PHASE 3 GRANITE-1 TRIAL. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2012.
46. Andre, Thierry Jose Maria, Vieitez Bouche, Olivier Bennouna, Jaafar Sastre, Javier Alonso-Orduna, Vicente Arnold, Dirk Osterlund, Pia Greil, Richard Van Cutsem, Eric von Moos, Roger Reyes-Rivera, Irmarie Makrutzki, Martina Kubicka S. BEVACIZUMAB plus CHEMOTHERAPY BEYOND FIRST PROGRESSION IN METASTATIC COLORECTAL CANCER PATIENTS PREVIOUSLY TREATED WITH BEVACIZUMAB-BASED THERAPY: TML STUDY SUBGROUP FINDINGS. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2012.
47. Van Cutsem E, Maria Vieitez J, Bouche O, Osterlund P, Bennouna J, Andre T, et al. RANDOMISED PHASE III STUDY OF BEVACIZUMAB plus CHEMOTHERAPY BEYOND PROGRESSION IN BEVACIZUMAB-TREATED PATIENTS WITH METASTATIC COLORECTAL CANCER: TML STUDY KRAS SUBGROUP FINDINGS. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2012.
48. Sobrero, Alberto Grothey, Axel Van Cutsem, Eric Siena, Salvatore Falcone, Alfredo Ychou, Marc Humblet, Yves Bouche, Olivier Mineur, Laurent Barone, Carlo Adenis, Antoine Tabernero, Josep Yoshino, Takayuki Lenz, Heinz Joseph Goldberg, Richard Cihon, Frank D. PHASE 3 CORRECT TRIAL OF REGORAFENIB IN METASTATIC COLORECTAL CANCER (MCRC). World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2012.
49. Taieb, Julien Tabernero, Josep Mini, Enrico Subtil, Fabien Folprecht, Gunnar Van Laethem, Jean-Luc Thaler, Josef Bridgewater, John Sanches, Evaristo Petersen, Lone Norgard Rougier, Philippe Collette, Laurence Praet, Michel Girault, Cecile Schneider, Marti C. ADJUVANT FOLFOX4+/- CETUXIMAB IN KRAS WILD-TYPE PATIENTS WITH RESECTED STAGE III COLON CANCER RESULTS FROM THE PETACC8 INTERGROUP TRIAL. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2012.
50. Nordlinger, Bernard Sorbye, Halfdan Glimelius, Bengt Poston, Graeme John Schlag, Peter M. Rougier, Philippe Bechstein, Wolf Primrose, John Neil Walpole, Euan Thomas Finch-Jones, Meg Jaeck, Daniel Mirza, Darius Parks, Rowan W. Collette, Laurence Praet, Mic T. LONG TERM SURVIVAL DATA FROM EORTC STUDY 40983: PERIOPERATIVE CHEMOTHERAPY FOR RESECTABLE LIVER METASTASES FROM COLORECTAL CANCER. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2012.
51. Joulain, Florence Iqbal, Sheikh Diamand, Francoise Van Cutsem, Eric Hoyle, Martin Allegra C. AFLIBERCEPT VERSUS PLACEBO IN COMBINATION WITH FOLFIRI IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER: MEAN OVERALL SURVIVAL FOR SUBGROUPS FROM VELOUR. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2012.
52. Van Cutsem E, Yeh K-H, Bang Y-J, Shen L, Ajani JA, Bai Y-X, et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. ASCO Meet. Abstr. . 2012 Jan 30;30 (4_suppl ):LBA3.
53. Kang Y-K, Ryoo B-Y, Chang H-M, Zang DY, Kim TW, Yang DH, et al. Update of AMC 0101 study: A phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short-term doxifluridine (Mf) as adjuvant chemotherapy for grossly serosa-positive . ASCO Meet. Abstr. . 2012 Jan 30;30 (4_suppl ):4.
54. Ryoo B-Y, Kang Y-K, Min YJ, Zang DY, Kim GY, Yang DH, et al. Update of AMC 0201 study: A randomized phase III trial comparing mitomycin-C plus short-term doxifluridine (Mf) versus mitomycin-C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer (NCT00296335). ASCO Meet. Abstr. . 2012 Jan 30;30 (4_suppl ):76.
55. Shen L, Li J, Xu J-M, Pan H-M, Dai G, Qin S, et al. Efficacy and tolerability of bevacizumab (BEV) plus capecitabine and cisplatin (XP) in Chinese patients (pts) with locally advanced or metastatic gastric/gastroesophageal junction cancer (AGC): Results from the AVATAR study. ASCO Meet. Abstr. . 2012 Jan 30;30 (4_suppl ):73.
56. Shah MA, Van Cutsem E, Kang Y-K, Dakhil SR, Satoh T, Chin K, et al. Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. ASCO Meet. Abstr. . 2012 Jan 30;30 (4_suppl ):5.
57. Grothey A, Sobrero AF, Siena S, Falcone A, Ychou M, Lenz H-J, et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after st. ASCO Meet. Abstr. . 2012 Jan 30;30 (4_suppl ):LBA385.
58. Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, et al. Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20. ASCO Meet. Abstr. 2012.
59. Sobrero AF, Peeters M, Price TJ, Hotko Y, Cervantes-Ruiperez A, Ducreux M, et al. Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). ASCO Meet. Abstr. . 2012 Jan 30;30 (4_suppl ):387.
60. Schmoll H-J, Tabernero J, Maroun JA, De Braud FG, Price TJ, Van Cutsem E, et al. Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA). ASCO Meet. Abstr. . 2012 Jan 30;30 (4_suppl ):388.
61. Francois E, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne P-L, et al. Influence of age on chemoradiotherapy outcome in patients with rectal cancer: Exploratory analysis from the phase III study ACCORD 12/0405 PRODIGE 2. ASCO Meet. Abstr. . 2012 Jan 30;30 (4_suppl ):550.
62. Gerard J-P, Azria D, Gourgou-Bourgade S, Conroy T, Bedenne L. Clinical results at 3 years of the ACCORD 12 randomized trial in rectal cancer. ASCO Meet. Abstr. . 2012 Jan 30;30 (4_suppl ):389.
63. Seymour MT, Brown SR, Richman S, Middleton GW, Maughan TS, Maisey N, et al. 6007 ORAL Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification. Eur. J. Cancer. 2011;47.
64. Middleton GW, Brown SR, Gwyther SJ, Maughan TS, Wadsley J, Chau I, et al. 6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer – Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification. Eur. J. Cancer. 2011;47:S420–S421.
65. Burkes R, Siena S, Cassidy J, Tabernero J, Barugel ME, Humblet Y, et al. 6095 POSTER Randomized, Open-label, Phase 3 Study of Panitumumab (Pmab) With FOLFOX4 Vs FOLFOX4 Alone as 1st-line Treatment for Metastatic Colorectal Cancer (mCRC) – the Role of Hypomagnesemia (Hypomag) on Efficacy. Eur. J. Cancer. 2011;47.
66. Taeib, J; Tabernero, J; Mini E et al. ADJUVANT FOLFOX4 WITH OR WITHOUT CETUXIMAB (CTX) IN PATIENTS (PTS) WITH RESECTED STAGE III COLON CANCER (CC): DFS AND OS RESULTS AND SUBGROUP ANALYSES OF THE PETACC8 INTERGROUP PHASE III TRIAL. ESMO. Vienna, AUSTRIA; 2012.
67. Price T, Peeters M, Strickland A, Ciuleanu TE, Scheithauer W, O’Reilly S, et al. 6132 POSTER Efficacy of Panitumumab Plus FOLFIRI Versus FOLFIRI Alone in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) Treated With Prior Oxaliplatin or Bevacizumab Regimens: Results From 20050181. Eur. J. Cancer. 2011;47:S431–S432.
68. Min YJ, Kang YK, Ryoo BY, Zang DY, Kim GY, Yang DH, et al. 6570 POSTER Update of AMC 0201 Study – a Randomized Phase III Trial Comparing Mitomycin-C Plus Short-term Doxifluridine (Mf) Versus Mitomycin-C Plus Long-term Doxifluridine Plus Cisplatin (MFP) After Curative Resection of Advanced Gastric Cancer (NCT00296. Eur. J. Cancer. 2011;47.
69. Kanq YK, Ryu MH, Chang HM, Zang DY, Kim TW, Yang DH, et al. 6505 ORAL Update of AMC 0101 Study – a Randomized Phase III Trial of Intraperitoneal Cisplatin and Early Mitomycin-C Plus Long-term Doxifluridine Plus Cisplatin (iceMFP) Versus Mitomycin-C Plus Short-Term Doxifluridine (Mf) as Postoperative Adjuvant Chemo. Eur. J. Cancer. 2011;47:S443–S444.
70. Lombard-Bohas C, Van Cutsem E, Capdevila J, de Vries EGE, Tomassetti P, Lincy J, et al. 6561 POSTER Updated Survival and Safety Data From RADIANT-3 – a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Trial of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET). Eur. J. Cancer. 2011;47.
71. Baudin E, Wolin E, Castellano D, Kaltsas G, Panneerselvam A, Tsuchihashi Z, et al. 6564 POSTER Correlation of PFS With Early Response of Chromogranin A and 5-hydroxyindoleacetic Acid Levels in Pts With Advanced Neuroendocrine Tumours: Phase III RADIANT-2 Study Results. Eur. J. Cancer. 2011;47.
72. Pavel M, Singh N, Passos V, Oberg K. 6571 POSTER Impact of Prior Somatostatin Analog (SSA) Use on PFS in the Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Patients With Advanced Neuroendocrine Tumours (RADIANT-2). World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2011. p. S462–S463.
73. Fazio N, Granberg D, Grossman A, Saletan S, Winkler RE, Panneerselvam A, et al. 6572 POSTER Effect of Everolimus + Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumours – Analysis From RADIANT-2. Eur. J. Cancer. 2011;47.
74. Valle J, Niccoli P, Raoul JL, Bang YJ, Borbath I, Van Cutsem E, et al. 6569 POSTER Updated Overall Survival Data From a Phase III Study of Sunltlnlb Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET). Eur. J. Cancer. 2011;47.
75. Watkins DJ, Tabernero J, Schmoll H, Trarbach T, Ramos FJ, Howe J, et al. A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3501.
76. Roh MS, Yothers GA, O’Connell MJ, Beart RW, Pitot HC, Shields AF, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3503.
77. Hofheinz R, Wenz FK, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3504.
78. Allegra CJ, Yothers GA, O’Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3508.
79. Andre T, Van Cutsem E, Schmoll H, Tabernero J, Clarke S, Moore MJ, et al. A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3509.
80. Douillard J, Siena S, Cassidy J, Tabernero J, Burkes RL, Barugel ME, et al. Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3510.
81. Siena S, Cassidy J, Tabernero J, Burkes RL, Barugel ME, Humblet Y, et al. Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3567.
82. Sauer R, Liersch T, Merkel S, Becker H, Hohenberger W, Witzigmann H, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3516.
83. Alberts SR, Thibodeau SN, Sargent DJ, Mahoney MR, Sinicrope F, Shields AF, et al. Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3607.
84. Huang J, Sargent DJ, Mahoney MR, Shields AF, Chan E, Goldberg RM, et al. Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3522.
85. Seymour MT, Brown SR, Richman S, Middleton GW, Maughan T, Olivier C, et al. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3523.
86. Middleton GW, Gwyther SJ, Brown SR, Maughan T, Olivier C, Richman S, et al. Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3566.
87. Park YS, Lim HY, Lee J, Kim TW, Hong YS, Kim SY, et al. A randomized phase III study of sox (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3524.
88. Baba H, Muro K, Yasui H, Shimada Y, Tsuji A, Sameshima S, et al. Updated results of the FIRIS study: A phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3562.
89. Peeters M, Price TJ, Strickland AH, Ciuleanu TE, Scheithauer W, O’Reilly S, et al. Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3574.
90. Stintzing S, Neumann J, Jung A, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3575.
91. Elimova E, O’Callaghan CJ, Tu D, Karapetis CS, Price TJ, Zhu L, et al. Cetuximab (CET)-related hypersensitivity reactions (HSRs): An analysis of timing, demographics, and outcomes from the AGITG/NCIC CTG CO.17 trial. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3624.
92. Vickers MM, Karapetis CS, Tu D, O’Callaghan CJ, Price TJ, Tebbutt NC, et al. The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3601.
93. O’Callaghan CJ, Tu D, Karapetis CS, Au H, Moore MJ, Tebbutt NC, et al. The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3588.
94. Van Hazel GA, Tu D, Tebbutt NC, Jonker DJ, Price TJ, O’Callaghan C, et al. Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3602.
95. Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, et al. Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):3621.
96. Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4000.
97. Bang Y, Kim YW, Yang H, Chung HC, Park Y, Lee K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):LBA4002.
98. Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson R, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CR. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4003.
99. Park SH, Lim DH, Park K, Lee S, Oh SY, Kwon H, et al. A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4004.
100. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Benson AB, Thomas CR, et al. Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4005.
101. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, Mcdonald A, et al. Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):LBA4006.
102. Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Fukutomi A, Sugimori K, et al. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4007.
103. Raymond E, Niccoli P, Raoul J, Bang Y, Borbath I, Lombard-Bohas C, et al. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4008.
104. Wolin EM, Fazio N, Saletan S, Winkler RE, Panneerselvam A, Kvols L. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4075.
105. Anthony LB, Peeters M, Hainsworth JD, Baudin E, Hoersch D, Klimovsky J, et al. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4078.
106. Strosberg JR, Lincy J, Winkler RE, Wolin EM. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4009.
107. Yao JC, Ricci S, Winkler RE, Jehl V, Pavel ME. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4011.
108. Shah MH, Lombard-Bohas C, Ito T, Wolin EM, Van Cutsem E, Sachs C, et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4010.
109. Pommier RF, Wolin EM, Panneerselvam A, Saletan S, Winkler RE, Van Cutsem E. Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): Results from the RADIANT-3 trial. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4103.
110. Fujii M, Kim YH, Satoh T, Hosaka H, Kim T, Tsuji A, et al. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial update. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4016.
111. Lim HY, Lee J, Chang H, Kim JS, Choi HJ, Lee MA, et al. Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma. ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):LBA4032.
112. Kang Y, Ohtsu A, Van Cutsem E, Roman L, Nunes J, Li C, et al. Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC). ASCO Meet. Abstr. . 2011 Jun 9;29 (15_suppl ):4119.
113. Baudin, Eric, Castellano, Daniel, Kaltsas, Gregory. CORRELATION OF PFS AND CHROMOGRANIN A AND 5-HYDROXYINDOLEACETIC ACID LEVELS IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS: PHASE III RADIANT-2 STUDY RESULTS. World Congr. Gastrointest. Cancer. Milan, Italy; 2011.
114. Castellano, Daniel, Bajetta, Emilio, Panneerselvam, Ashok. SUBGROUP ANALYSIS OF PATIENTS WITH COLORECTAL NEUROENDOCRINE TUMORS (NET) IN THE PHASE III RADIANT-2 STUDY COMPARING EVEROLIMUS PLUS OCTREOTIDE LAR WITH PLACEBO PLUS OCTREOTIDE LAR. World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2011.
115. Pavel, Marianne, Vries D, Elisabeth, Oberg, Kjell. EVEROLIMUS IMPROVES PROGRESSION-FREE SURVIVAL (PFS) REGARDLESS OF BASELINE CHROMOGRANIN A (CgA) AND NEURON-SPECIFIC ENOLASE (NSE) LEVELS IN PATIENTS WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (pNET) (RADIANT-3). World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2011.
116. Cutsem V, Eric, Tabernero, Josep, Lakomy, Radek. INTRAVENOUS (IV) AFLIBERCEPT VERSUS PLACEBO IN COMBINATION WITH IRINOTECAN/5-FU (FOLFIRI) FOR SECOND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF A MULTINATIONAL PHASE III TRIAL (EFC10262-VELOUR). World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2011.
117. Peeters, Marc, Oliner, S. K, Siena, Salvatore. ASSESSMENT OF TUMOR GENOTYPES IN METASTATIC COLORECTAL CANCER (MCRC): MUTATIONS BEYOND KRAS CODONS 12 AND 13 AS PREDICTIVE BIOMARKERS OF RESPONSE TO PANITUMUMAB (PMAB) IN A RANDOMIZED, PHASE 3 STUDY. World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2011.
118. Siena, Salvatore, Cassidy, James, Tabernero, Josep. EFFICACY AND SAFETY BY EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS (PS) IN PATIENTS RECEIVING PANITUMUMAB (PMAB) WITH FOLFOX4 AS 1(st)-LINE TREATMENT FOR WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (MCRC). World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2011.
119. Ito T, Okusaka T, Ikeda M, Tajima T, Kasuga A, Fujita Y, et al. Everolimus versus placebo in Japanese patients with advanced pancreatic neuroendocrine tumors (pNET): Japanese subgroup analysis of RADIANT-3. ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):289.
120. Yao JC, Hainsworth JD, Baudin E, Peeters M, Hoersch D, Anthony LB, et al. Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2). ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):159.
121. Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Sachs C, et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3). ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):158.
122. De Gramont A, Van Cutsem E, Tabernero J, Moore MJ, Cunningham D, Rivera F, et al. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):362.
123. Huang J, Sargent DJ, Mahoney MR, Thibodeau SN, Smyrk TC, Sinicrope F, et al. Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147. ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):363.
124. Kim YH, Koizumi W, Lee KH, Kishimoto T, Chung HC, Hara T, et al. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial. ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):7.
125. Okusaka T, Makuuchi M, Matsui O, Kumada H, Tanaka K, Kaneko S, et al. Clinical benefit of peretinoin for the suppression of hepatocellular carcinoma (HCC) recurrence in patients with Child-Pugh grade A (CP-A) and small tumor: A subgroup analysis in a phase II/III randomized, placebo-controlled trial. ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):165.
126. Tveit K, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer . ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):365.
127. Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, et al. Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC). ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):510.
128. Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N, et al. The use of trastuzumab in Japanese patients with HER2-positive advanced or metastatic gastric cancer. ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):102.
129. Thongprasert S, Qin S, Lim H, Bhudhisawasdi V, Yin X, Gang W, et al. Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin in advanced HCC: Updates on the EACH study. ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):160.
130. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Benson AB, Thomas CR, et al. Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: Comparison of concurrent chemoradiation with 5FU-mitomycin versus 5FU-cisplatin for disease-free and overall survival. ASCO Meet. Abstr. . 2011 Feb 3;29 (4_suppl ):367.
131. Pavel, M., Hainsworth, D. J, Baudin, E. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III TRIAL OF EVEROLIMUS plus OCTREOTIDE LAR VS PLACEBO plus OCTREOTIDE LAR IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS (NET) (RADIANT-2). ESMO. Milan, Italy; 2010. p. 4–4.
132. Yao, C. J, Shah, H. M, Ito, T. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III TRIAL OF EVEROLIMUS IN PATIENTS WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET) (RADIANT-3). ESMO. Milan, Italy; 2010. p. 4–5.
133. Hoff, M. P, Hochhaus, A., Pestalozzi, C. B. CEDIRANIB plus FOLFOX/XELOX VERSUS PLACEBO plus FOLFOX/XELOX IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY (HORIZON II). ESMO. Milan, Italy; 2010. p. 9–9.
134. Tveit, K., Guren, T., Glimelius, B. RANDOMIZED PHASE III STUDY OF 5-FLUOROURACIL/FOLINATE/OXALIPLATIN GIVEN CONTINUOUSLY OR INTERMITTENTLY WITH OR WITHOUT CETUXIMAB, AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: THE NORDIC VII STUDY (NCT00145314), BY THE NORDIC COLORECTAL CANCER. ESMO. Milan, Italy; 2010. p. 9–9.
135. Schmoll, H., Cunningham, D., Sobrero, A. MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III). ESMO. Milan, Italy; 2010. p. 189–189.
136. Piessevaux, H., Schlichting, M., Heeger, S. EARLY TUMOR SHRINKAGE FOR THE PREDICTION OF EFFICACY OF CETUXIMAB IN METASTATIC COLORECTAL CANCER (MCRC): ANALYSIS FROM THE CRYSTAL STUDY. ESMO. Milan, Italy; 2010. p. 193–4.
137. Stathopoulos, G. P. Batziou, C. Trafalis, D. Koutantos, J. Batzios, S. Stathopoulos, J. Legakis, J. Armacolas A. CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN ADVANCED COLORECTAL CANCER: A PHASE III TRIAL. ESMO. Milan, Italy: OXFORD UNIV PRESS; 2010.
138. Papadimitriou, C. A. Papakostas, P. Bournakis, E. Karina, M. Dimopoulos, M. A. Pentheroudakis, G. Pectasides, D. Bafaloukos, D. Kalofonos, H. P. Fountzilas G. A RANDOMIZED PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH IRINOTECAN, LEUCOVORIN AND FLUOROURACIL VERSUS LEUCOVORIN AND FLUOROURACIL FOR STAGE II AND III COLON CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY. ESMO. Milan, Italy: OXFORD UNIV PRESS; 2010.
139. Haller, D. Cassidy, J. Tabernero, J. Maroun, J. A. De Braud, F. Price, T. J. van Cutsem, E. Hill, M. Gilberg, F. Schmoll H. RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): IMPACT OF AGE ON DISEASE-FREE SURVIVAL (DFS) OR OVERALL SURVIVAL (OS). ESMO. Milan, Italy: OXFORD UNIV PRESS; 2010.
140. Twelves, C. Scheithauer, W. McKendrick, J. Nowacki, M. Seitz, J. van Hazel, G. Wong, A. Diaz-Rubio, E. Gilberg, F. Cassidy J. EFFICACY FINDINGS FROM THE X-ACT TRIAL OF CAPECITABINE VS. 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER: NO IMPACT OF AGE ON DISEASE-FREE SURVIVAL OR OVERALL SURVIVAL. ESMO. Milan, Italy: OXFORD UNIV PRESS; 2010.
141. Valle, J. Faivre, S. Raoul, J. Bang, Y. Patyna, S. Lu, D. R. Chao, R. Raymond E. PHASE III TRIAL OF SUNITINIB (SU) VERSUS PLACEBO (PBO) FOR TREATMENT OF PANCREATIC NEUROENDOCRINE TUMORS (NET): IMPACT OF SOMATOSTATIN ANALOGUE (SSA) TREATMENT ON PROGRESSION-FREE SURVIVAL (PFS). ESMO. Milan, Italy: OXFORD UNIV PRESS; 2010.
142. Guimbaud, R., Louvet, C., Bonnetain, F. FINAL RESULTS OF THE INTERGROUP FFCD-GERCOR-FNCLCC 03-07 PHASE III STUDY COMPARING TWO SEQUENCES OF CHEMOTHERAPY IN ADVANCED GASTRIC CANCERS. ESMO. Milan, Italy; 2010. p. 250–250.
143. Desseigne, F., Ychou, M., Ducreux. FINAL RESULTS OF A RANDOMIZED PHASE III TRIAL COMPARING FOLFIRINOX (F: 5FU/LEUCOVORIN [LV], IRINOTECAN [I] AND OXALIPLATIN [O]) VS GEMCITABINE (G) AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC ADENOCARCINOMA (MPA). THE PRODIGE 4/ACCORD 11 TRIAL. ESMO. Milan, Italy; 2010. p. 251–251.
144. Qin, S. Thongprasert, S. Lim, H. Y. Liang, L. Zhang, Y. Rau, K. Yang, T. Seetalakom, K. Kim, J. H. Zhou Y. OXALIPLATIN+5-FLUOROURACIL/LEUCOVORIN (FOLFOX4) IN ADVANCED HCC: UPDATED EFFICACY RESULTS OF THE EACH TRIAL. ESMO. Milan, Italy: OXFORD UNIV PRESS; 2010.
145. Sasako, M., Kinoshita, T., Furukawa, H. FIVE-YEAR RESULTS OF THE RANDOMIZED PHASE III TRIAL COMPARING S-1 MONOTHERAPY VERSUS SURGERY ALONE FOR STAGE II/III GASTRIC CANCER PATIENTS AFTER CURATIVE D2 GASTRECTOMY (ACTS-GC STUDY). ESMO. Milan, Italy; 2010. p. 225–225.
146. Van Cutsem, E. Shah, M. Kang, Y. Yamada, Y. Yamaguchi, K. Nishina, T. Doi, T. Wu, J. Langer, B. Ohtsu A. RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE III STUDY OF CAPECITABINE/CISPLATIN plus BEVACIZUMAB (BEV) OR PLACEBO (PL) AS 1ST-LINE THERAPY IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER (AGC) (AVAGAST UPDATE). ESMO. Milan, Italy: OXFORD UNIV PRESS; 2010.
147. Tabernero J, Aranda E, Gomez A, Massuti B, Sastre J, Abad A, et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for . ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3501.
148. Maughan TS, Adams R, Smith CG, Seymour MT, Wilson RH, Meade AM, et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3502.
149. Adams R, Wilson RH, Seymour MT, Meade AM, Madi A, Cassidy J, et al. Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC . ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3525.
150. Goldberg RM, Sargent DJ, Thibodeau SN, Mahoney MR, Shields AF, Chan E, et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3508.
151. Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. ASCO Meet. Abstr. . 2010 Jun 22;28 (18_suppl ):CRA3507.
152. Haller DG, Cassidy J, Tabernero J, Maroun JA, De Braud FG, Price TJ, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS). ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3521.
153. Tournigand C, Andre T, Bachet j., Teixeira L, Boni C, Clingan PR, et al. FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3522.
154. Teixeira L, Hickish T, Tournigand C, Bachet J, Bonetti A, Rivera F, et al. Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3524.
155. Douillard J, Cassidy J, Jassem J, Rivera F, Kocakova I, Rogowski W, et al. Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3528.
156. Price TJ, Sobrero AF, Wilson G, Van Cutsem E, Aleknaviciene B, Zaniboni A, et al. Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3529.
157. Pectasides DG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papaxoinis G, et al. Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3541.
158. Ziras N, Polyzos A, Xenidis N, Kalykaki A, Androulakis NE, Papakotoulas P, et al. CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC). ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3542.
159. Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, et al. Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):3544.
160. Niccoli P, Raoul J, Bang Y, Borbath I, Lombard-Bohas C, Valle JW, et al. Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):4000.
161. Gaast A V, van Hagen P, Hulshof M, Richel D, van Berge Henegouwen MI, Nieuwenhuijzen GA, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):4004.
162. Mariette C, Seitz JF, Maillard E, Mornex F, Thomas PA, Raoul J, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):4005.
163. Kang Y, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park S, et al. AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). ASCO Meet. Abstr. . 2010 Jun 22;28 (18_suppl ):LBA4007.
164. Qin S, Bai Y, Ye S, Fan J, Lim H, Cho JY, et al. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):4008.
165. Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):4010.
166. Boeck SH, Vehling-Kaiser U, Waldschmidt D, Kettner E, Marten A, Winkelmann C, et al. Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkolo. ASCO Meet. Abstr. . 2010 Jun 22;28 (18_suppl ):LBA4011.
167. Okita K, Matsui O, Kumada H, Tanaka K, Kaneko S, Moriwaki H, et al. Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):4024.
168. Raymond E, Niccoli P, Raoul J, Bang Y, Borbath I, Lombard-Bohas C, et al. Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups of patients (pts) with progressive pancreatic neuroendocrine tumors (NET). ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):4031.
169. Raoul J, Sherman M, Nadel A, Lentini G, Moscovici MM, Voliotis D, et al. Efficacy and safety of sorafenib (Sor) in patients (Pts) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP trial by baseline (BL) transaminase (ALT/AST)/{alpha}-fetoprotein (AFP) and bilirubin (bil) levels. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):4051.
170. Vickers MM, Powell ED, Asmis TR, Jonker DJ, O’Callaghan CJ, Tu D, et al. Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine (E+G) versus gemcitabine (G) alone. ASCO Meet. Abstr. . 2010 Jun 14;28 (15_suppl ):4079.
171. Twelves, C. Scheithauer, W. McKendrick, J. Nowacki, M. Seitz, J. Van Hazel, G. Wong, A. Diaz-Rubio, E. Gilberg, F. Cassidy J. EFFICACY FINDINGS FROM THE X-ACT TRIAL OF CAPECITABINE VS. 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER: NO IMPACT OF AGE ON DISEASE-FREE SURVIVAL OR OVERALL SURVIVAL. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2010.
172. Haller, D. Cassidy, J. Tabernero, J. Maroun, J. De Braud, F. Price, T. Van Cutsem, E. Hill, M. Gilberg, F. Schmoll H. EFFICACY FINDINGS FROM A RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): NO IMPACT OF AGE ON DISEASE-FREE SURVIVAL. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2010.
173. Riess, H., Manges, R., Karasek, P. DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED PHASE III TRIAL OF AFLIBERCEPT (A) PLUS GEMCITABINE (G) VERSUS PLACEBO (P) PLUS GEMCITABINE (G) IN PATIENTS WITH METASTATIC PANCREATIC CANCER: FINAL RESULTS. World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2010. p. 12–12.
174. Van Cutsem, E. Macarulla, T. Van Laethem, J. Couture, F. Peeters, M. Hoff, Gehn M. Roman, L. Lequesne, L. Charpentier, E. Conroy T. A PHASE III STUDY COMPARING LAROTAXEL TO 5-FU (CONTINUOUS INTRAVENOUS 5-FU OR CAPECITABINE) IN PATIENTS WITH ADVANCED PANCREATIC CANCER (APC) PREVIOUSLY TREATED WITH A GEMCITABINE CONTAINING REGIMEN. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2010.
175. Qin, S. Fan, J. Lim, H. Kang, W. Cho, J. Thongprasert, S. Bhudhisawasdi, V Chao, Y. Yang, T. Shen, W. Sun Y. PHASE III STUDY OF FOLFOX4 VS. DOXORUBICIN IN ASIAN PATIENTS WITH ADVANCED HCC: SUBGROUP ANALYSES ACCORDING TO BASELINE DISEASE STATUS. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2010.
176. Raymond, E. Niccoli, P. Raoul, J. Bang, Y. Borbath, I Lombard-Bohas, C. Valle, J. Hoersch, D. Patyna, S. Lu, D. Korytowsky, B. Mundayat, R. Chao, R. Vinik A. EVIDENCE OF ACTIVITY AND CLINICAL BENEFIT WITH SUNITINIB IN PATIENTS WITH PANCREATIC NEUROENDOCRINE TUMORS (NET). World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2010.
177. Ohtsu, A., Cutsem V, E., Shah, M. AVAGAST: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE III STUDY OF CAPECITABINE/CISPLATIN + BEVACIZUMAB OR PLACEBO AS 1ST-LINE THERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER. World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2010. p. 14–14.
178. Peeters, M. Price, T. Hotko, Y. Cervantes, A. Ducreux, M. Andre, T. Chan, E. Lordick, F. Rong, A. Gansert J. RANDOMIZED PHASE 3 STUDY OF PANITUMUMAB (PMAB) WITH FOLFIRI COMPARED TO FOLFIRI ALONE AS SECOND-LINE TREATMENT (TX) FOR METASTATIC COLORECTAL CANCER (MCRC): SECONDARY ENDPOINT RESULTS. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2010.
179. Aranda E, Tabernero J, Gomez A, Yuste A, Puente J, Abad A, et al. MACRO/TTD PHASE III STUDY OF FIRST-LINE XELOX PLUS BEV FOR 6 CYCLES FOLLOWED BY XELOX PLUS BEV OR SINGLE AGENT (S/A) BEV AS MAINTENANCE THERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2010.
180. Maughan, T., Adams, R., Smith, C. THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS. World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2010. p. 17–8.
181. Adams, R., Wilson, Seymour, M. INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS. World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2010. p. 19–19.
182. Douillard, J. Siena, S. Cassidy, J. Tabernero, J. Burkes, R. Barugel, M. Humblet, Y. Cunningham, D. Wolf, M. Gansert J. RANDOMIZED PHASE 3 STUDY OF PANITUMUMAB (PMAB) WITH FOLFOX4 COMPARED TO FOLFOX4 ALONE AS FIRST LINE TREATMENT (TX) FOR METASTATIC COLORECTAL CANCER (MCRC): PRIME TRIAL. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2010.
183. Van Cutsem, E. Rougier, P. Lang, I. Folprecht, G. Nowacki, M. Barone, C. Shchepotin, I. Maurel, J. Cunningham, D. Celik, I. Koehne C. THE INFLUENCE OF KRAS AND BRAF TUMOR MUTATION STATUS ON TREATMENT OUTCOME WITH CETUXIMAB PLUS FOLFIRI: FINAL DATA FROM THE CRYSTAL STUDY. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2010.
184. Carrato, A., Swieboda-Sadlej, Staszewska-Skurczynska, M. FINAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB PLUS FOLFIRI VS. PLACEBO PLUS FOLFIRI IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC). World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2010. p. 19–19.
185. Guan, Z., Xu, J., Luo, R. BEVACIZUMAB PLUS CHEMOTHERAPY IN CHINESE PATIENTS WITH METASTATIC COLORECTAL CANCER: EFFICACY AND TOLERABILITY RESULTS FROM THE ARTIST STUDY. World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2010. p. 22–22.
186. Raymond, E; Niccoli-Sire, P; Bang Y et al. Updated results of the phase III trial of sunitinib versus placebo for treatment of advanced pancreatic neuroendocrine tumors. ASCO GI cancers Symp. San Francisco, USA; 2010.
187. Okita, K; Imanaka, K; Chida N et al. Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma treated after transarterial chemoembolisation. ASCO GI cancers Symp. San Francisco, USA; 2010.
188. Raoul, J; Sherman, M; Nadel A et al. Efficiency and safety of sorafenib in patients with advanced hepatocellular carcinoma: subgroup analyses of the SHARP trial by baseline transaminase/alpha-fetoprotein and bilirubin levels. ASCO GI cancers Symp. San Francisco, USA; 2010.
189. Siena, S; Cassidy, J; Tabernero J et al. Randomised phase III study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as first-line treatment for metastatic colorectal cancer: PRIME trial. ASCO GI cancers Symp. San Francisco, USA; 2010.
190. Haller, D; Cassidy, J; Tabernero J et al. Efficiency findings from a randomised phase III trial of capecitabine plus oxaliplatin versus bolus 5FU/LV for stage III colon cancer(N016968): no impact of age on disease-free survival. ASCO GI cancers Symp. San Francisco, USA; 2010.
191. Yothers, G; O’Connell, M; Colangelo L et al. 5-FU and leucovorin with or without oxaliplatin for adjuvant treatment of stage II and III colon cancer: long term follow-up of NSABP C-07 with survival analysis. ASCO GI cancers Symp. San Francisco, USA; 2010.
192. Maughan, T; Adams RS et al. Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: the effect of infusional 5-FU or capecitabine on the outcomes of the MRC COIN in advanced colorectal cancer. ASCO GI cancers Symp. San Francisco, USA; 2010.
193. Adams, R; Wilson, R; Seymour M et al. Intermittent versus continuous oxaliplatin-based combination chemotherapy in first-line treatment of patients with advanced colorectal cancer: first analysis of quality of life and updated efficacy results from the MRC COIN trial. ASCO GI cancers Symp. San Francisco, USA; 2010.
194. Tebbutt, N. Gebski, V. Wilson, K. Cummins, M. Robinson, B. Broad, A. Cunningham, D. Simes, J. Stockler, M. Price T. International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial. ECCO. Berlin, Germany: PERGAMON-ELSEVIER SCIENCE LTD; 2009.
195. Kato, K., Muro, Yasui, H. The FIRIS study; A Phase III trial of 5-FU/I-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as 2nd-line chemotherapy for metastatic colorectal cancer (mCRC) [FIRIS study group]. ECCO. Berlin, Germany; 2009. p. 324–5.
196. Masi G, Salvatore L, Fornaro L, Vasile E, Baldi GG, Stasi I, et al. Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II GONO trial. ECCO. Berlin, Germany: PERGAMON-ELSEVIER SCIENCE LTD; 2009.
197. Badulescu, F. Badulescu, A. Schenker, M. Ionescu, M. Ninulescu, C. Crisan, A. Dinescu S. FOLFOX-4 versus FOLFIRI in the treatment of metastatic colorectal cancer - a prospective randomised study. ECCO. Berlin, Germany: PERGAMON-ELSEVIER SCIENCE LTD; 2009.
198. Bridgewater, J., Valle, Palmer, D. Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): final results of the UK ABC-02 trial. ECCO. Berlin, Germany; 2009. p. 361–361.
199. Raoul, L. J, Niccoli, P., Bang, J. Y. Sunitinib (SU) vs placebo for treatment of progressive, well-differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial. ECCO. Berlin, Germany; 2009. p. 361–361.
200. Raymond, E., Raoul, J., Niccoli, P. PHASE III, RANDOMIZED, DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMOURS. World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2009. p. 11–11.
201. Kindler, H. L. Ioka, T. Richel, D. J. Bennouna, J. Letourneau, R. Okusaka, T. Bycott, P. Ricart, A. D. Kim, S. Van Cutsem E. A double-blinded, placebo-controlled, randomized, phase III study of axitinib (AG-013736; A) plus gemcitabine (G) vs. G plus placebo (P) in advanced pancreatic cancer (PC) patients (pts). ECCO. Berlin, Germany: PERGAMON-ELSEVIER SCIENCE LTD; 2009.
202. Sawaki, A., Yamaguchi, K., Nabeya, Y. 5-FU/I-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial. (ISO-5FU10 Study Group trial). ECCO. Berlin, Germany; 2009. p. 364–364.
203. Bartolomeo D, M., Buzzoni, R., Vullo L, S. Sequential therapy with FOLFIRI followed by docetaxel plus cisplatin: a promising adjuvant chemotherapy in gastric adenocarcinoma. 5-year follow-up results of the ITMO Group study. ECCO. 2009. p. 364–364.
204. Gerard J, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne P, et al. Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):LBA4007.
205. Aschele C, Pinto C, Cordio S, Rosati G, Tagliagambe A, Artale S, et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. ASCO Meet. Abstr. . 2009 Jun 18;27 (18S ):CRA4008.
206. Wolmark N, Yothers G, O’Connell MJ, Sharif S, Atkins JN, Seay TE, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):LBA4.
207. James R, Wan S, Glynne-Jones R, Sebag-Montefiore D, Kadalayil L, Northover J, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):LBA4009.
208. Piedbois P, Ychou M, Zawadi A, Douillard J, Guerin-Meyer V, Andre T, et al. Interim efficacy analysis of the French Intergroup R98 trial comparing 5FU-leucovorin alone or with irinotecan (CPT-11) in resected stages II-III rectal cancers. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4015.
209. Tebbutt NC, Gebski V, Wilson K, Cummins M, Chua Y, Robinson B, et al. International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4023.
210. Conroy T, Ducreux M, Lemanski C, Francois E, Giovannini M, Cvitkovic F, et al. Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4033.
211. Hurwitz H, Patt YZ, Henry D, Garbo L, Mitchell EP, Kohles J, et al. Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): Interim analysis. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4078.
212. Gamelin E, Mineur L, Chevelle C, Cailleux P, Martin L, Bastit L, et al. Neoadjuvant radiotherapy {+/-} tegafur-uracil plus leucovorin in rectal adenocarcinoma: Final results of a French multicenter phase III study. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4104.
213. Valle JW, Wasan HS, Palmer DD, Cunningham D, Anthoney DA, Maraveyas A, et al. Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4503.
214. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B, et al. A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas-- GOIM/GISCAD/GOIRC) study. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4504.
215. Neoptolemos J, Buchler M, Stocken DD, Ghaneh P, Smith D, Bassi C, et al. ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):LBA4505.
216. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):LBA4509.
217. Ajani JA, Rodriquez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4511.
218. Fuse N, Fukuda H, Yamada Y, Sawaki A, Koizumi W, Suzuki Y, et al. Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4514.
219. Macdonald JS, Benedetti J, Smalley S, Haller D, Hundahl S, Jessup J, et al. Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4515.
220. Verslype C, Vervenne W, Bennouna J, Humblet Y, Cosaert J, Van Cutsem E. Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4532.
221. Tsuburaya A, Narahara H, Imamura H, Hatake K, Imamoto H, Esaki T, et al. Updated result on the 2.5-year follow-up of GC0301/TOP-002: Randomized phase III study of irinotecan plus S-1 (IRI-S) versus S-1 alone as first-line treatment for advanced gastric cancer (AGC). ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4544.
222. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, et al. Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4545.
223. Qin S, Yang T, Tak W, Yu S, Tsao C, Kim J, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Asia-Pacific (AP) trial subgroup analyses by baseline transaminase (ALT/AST)/{alpha}-fetoprotein (AFP) levels. ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4590.
224. Buanes T, Maurel J, Liauw W, Hebbar M, Nemunaitis J. A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC). ASCO Meet. Abstr. . 2009 Jun 8;27 (15S ):4601.
225. Wasan, H., Valle, J., Palmer, D. GEMCITABINE WITH OR WITHOUT CISPLATIN IN PATIENTS (pts) WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER (ABC): RESULTS OF CA19.9 AND QUALITY OF LIFE ANALYSIS FOR THE UK ABC-02 TRIAL. World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2009. p. 9–9.
226. Bang, Y. Kang, Y. Chung, H. Shen, L. Sawaki, A. Lordick, F. Hill, J. Lehle, M. Feyereislova, A. Van Cutsem E. TRASTUZUMAB WITH CHEMOTHERAPY IN UNTREATED HER2-POSITIVE ADVANCED OR METASTATIC GASTRIC CANCER: EFFICACY RESULTS FROM THE ToGA TRIAL. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2009.
227. Aschele, C., Pinto, Cordio, S. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. world. Barcelona, SPAIN; 2009.
228. Rougier, P. Janciauskiene, R. Paramonov, V Shparyk, Y. Gustavsson, B. Wagnerova, M. Gorbunova, V Utracka-Hutka, B. Celik, I Van Cutsem E. UTILIZING PREDICTIVE BIOMARKERS TO IMPROVE TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): RESULTS WITH CETUXIMAB PLUS FOLFIRI IN THE CRYSTAL TRIAL. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2009.
229. Masi G, Vasile E, Loupakis F, Salvatore L, Fornaro L, Baldi G, et al. BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP. World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2009.
230. Midgley, J. RS, McConkey, C. C, Langman, J. M. VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION. ESMO. Stockholm, SWEDEN; 2008. p. 1–1.
231. Karapetis C, Khambata-Ford S, Jonker D, O’Callaghan C, Vachan B, Simes J, et al. KRAS MUTATION STATUS IS A PREDICTIVE BIOMARKER FOR CETUXIMAB BENEFIT IN THE TREATMENT OF ADVANCED COLORECTAL CANCER - RESULTS FROM NCIC CTG CO.17: A PHASE III TRIAL OF CETUXIMAB VERSUS BEST SUPPORTIVE CARE. ESMO. Stockholm, SWEDEN: OXFORD UNIV PRESS; 2008.
232. Van Cutsem E, Lang I, D’Haens G, Moiseyenko V, Zaluski J, Folprecht G, et al. KRAS STATUS AND EFFICACY IN THE CRYSTAL STUDY: 1ST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING FOLFIRI WITH OR WITHOUT CETUXIMAB. ESMO. Stockholm, SWEDEN: OXFORD UNIV PRESS; 2008.
233. Riess, H; Neuhaus, P; Post S et al. CONKO-001: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE, MULTICENTER PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS OBSERVATION IN PATIENTS WITH RESECTED PANCREATIC CANCER (PC). ESMO. Stockholm, SWEDEN: OXFORD UNIV PRESS; 2008.
234. Tol J, Koopman M, Antonini NF, Sinnige H, Valster FAA, ten Tije AJ, et al. RANDOMIZED PHASE III STUDY OF CAPECITABINE, OXALIPLATIN AND BEVACIZUMAB WITH OR WITHOUT CETUXIMAB IN ADVANCED COLORECTAL CANCER (ACC), THE CAIRO2 STUDY OF THE DUTCH COLORECTAL CANCER GROUP (DCCG). ESMO. Stockholm, SWEDEN: OXFORD UNIV PRESS; 2008.
235. Langer, C. Kopit, J. Awad, M. Teegarden, P. Xu, L. Khambata-Ford S. ANALYSIS OF K-RAS MUTATIONS IN PATIENTS WITH METASTATIC COLORECTAL CANCER RECEIVING CETUXIMAB IN COMBINATION WITH IRINOTECAN: RESULTS FROM THE EPIC TRIAL. ESMO. Stockholm, SWEDEN: OXFORD UNIV PRESS; 2008.
236. Cellier, P., Mineur, L., Chevelle, C. NEOADJUVANT UFT VS SUPPORTIVE CARE IN RECTAL ADENOCARCINOMA TREATED WITH RADIOTHERAPY AND SURGERY: A MULTICENTER PHASE III FRENCH STUDY. ESMO. Stockholm, SWEDEN; 2008. p. 167–167.
237. Guan, Z., Kang, Y., Chen. SORAFENIB IS EFFECTIVE IN HEPATITIS B-POSITIVE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): SUBGROUP ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL PERFORMED IN THE ASIA-PACIFIC REGION. ESMO. Stockholm, SWEDEN; 2008. p. 168–9.
238. Kang, Y., Guan, Z., Chen. SORAFENIB IS EFFECTIVE IN PATIENTS FROM THE ASIA-PACIFIC REGION WITH HEPATOCELLULAR CARCINOMA (HCC): SUBGROUP ANALYSIS OF MACROSCOPIC VASCULAR INVASION (MVI), EXTRAHEPATIC SPREAD (EHS), AND ECOG PERFORMANCE STATUS. ESMO. Stockholm, SWEDEN; 2008. p. 177–177.
239. Van Cutsem E, Lang I, D’haens G, Moiseyenko V, Zaluski J, Folprecht G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):2.
240. Wolmark N, Wieand S, Kuebler PJ, Colangelo L, O’Connell MJ, Yothers G. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):LBA4005.
241. Punt CJ, Tol J, Rodenburg CJ, Cats A, Creemers GM, Schrama JG, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):LBA4011.
242. Ychou M, Hohenberger W, Thezenas S, Navarro M, Gascon P, Bokemeyer C, et al. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301). ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):LBA4013.
243. Sanoff HK, Campbell ME, Pitot HC, Goldberg RM, Sargent DJ. Risk stratified analysis improves prediction of treatment (Rx) benefit over subgroup analysis: Findings from Intergroup N9741. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4018.
244. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Iveson CL, et al. VICTOR: A phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4038.
245. Popov I, Wils J, Carrato A, Sobrero A, Vincent M, Kerr DJ, et al. Final results of the PETACC-1 trial of bolus 5-FU/LV vs raltitrexed: An unsuccessful story? ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4053.
246. Piessevaux H, De Roock W, Van Cutsem E, Tejpar S. Use of tumor size decrease at 6 weeks (w) to predict response (OR), time to progression (TTP), and survival (OS) in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab (CTX) (BOND trial). ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4068.
247. O’Callaghan CJ, Tu D, Karapetis CS, Au HJ, Moore MJ, Zalcberg JR, et al. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4130.
248. Neuhaus P, Riess H, Post S, Gellert K, Ridwelski K, Schramm H, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):LBA4504.
249. Vervenne W, Bennouna J, Humblet Y, Gill S, Moore MJ, Van Laethem J, et al. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4507.
250. Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4509.
251. Igaki H, Kato H, Ando N, Shinoda M, Shimizu H, Nakamura T, et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4510.
252. Kang Y, Chang H, Zang D, Lee J, Kim T, Yang D, et al. Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: A randomized phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short- term doxifluridine (Mf) (AMC 0101) (NCT00296322). ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):LBA4511.
253. Ridwelski K, Fahlke J, Kettner E, Schmidt C, Keilholz U, Quietzsch D, et al. Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4512.
254. Mitry E, Dahan L, Ychou M, Arthaud J, Gasmi M, Raoul J, et al. LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301). ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4513.
255. Chang H, Kang Y, Min Y, Zang D, Kim G, Yang D, et al. A randomized phase III trial comparing mitomycin-C plus short-term doxifluridine (Mf) versus mitomycin-C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer (AMC 0201) (NCT00296335). ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4531.
256. Jin M, Lu H, Li J, Shen L, Chen Z, Shi Y, et al. Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4533.
257. Sherman M, Mazzaferro V, Amadori D, Seitz J, Moscovici M, Shan M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4584.
258. Raoul J, Santoro A, Beaugrand M, Marrero JA, Moscovici M, Shan M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial. ASCO Meet. Abstr. . 2008 Aug 18;26 (15_suppl ):4587.
259. Cassidy, J. Clarke, S. Diaz-Rubio, E. Scheithauer, W. Figer, A. Wong, R. Koski, S. Sirzen, F. Gilberg, F. Saltz L. Update of efficacy results from XELOX-1/NO16966, a randomised phase iii trial of XELOX vs. FOLFOX4 as first-line treatment for patients with metastatic colorectal cancer (MCRC). World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2008.
260. Rouigier P, Frangois SJ, Ychou M, Gasmi M, Dahan L, Raoul J, et al. 5-fluorouracil-leucovorin (LV5FU2)-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: A phase III trial (FFCD 0301). World Congr. Gastrointest. Cancer. Barcelona, SPAIN: OXFORD UNIV PRESS; 2008.
261. Ajani, A; Rodriguez, G; Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 with ciplatin/5-FU as first-line therapy in patients with advanced gastric cancer (FLAGS). ASCO GI cancers Symp. San Francisco, USA; 2009.
262. Van Cutsem, E; Vervenne, W; Bennouna J et al. Rash as a marker for the efficacy of gemcitabine and erlotinib-base therapy in pancreatic cancer: results from the AVITA study. ASCO GI cancers Symp. San Francisco, USA; 2009.
263. Guan, Z; Kang, Y; Chen Z et al. Impact of lung and lymph node metastasis on outcome following treatment with sorafenib in patients with hepatocellular carcinoma from the Asia-Pacific region. ASCO GI cancers Symp. San Francisco, USA; 2009.
264. Ychou, M; Dahan, L; Mitry E et al. LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: definitive results of a randomised phase III trial (FFCD 0301). ASCO GI cancers Symp. San Francisco, USA; 2009.
265. Cassidy, j; Clarke, S; Diaz-Rubio E et al. XELOX-1/N016966, a randomized phase III trial of XELOX compared with FOLFOX4 for patients with metastic colorectal cancer: updated survival and tolerability results. ASCO GI cancers Symp. San Francisco, USA; 2009.
266. Rougier, P; Stroiakovski, D; Kohne C et al. Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer: updated survival data and influence of of KRAS status on outcome in the CRYSTAL study. ASCO GI cancers Symp. San Francisco, USA; 2009.
267. Sasako, M; Yamaguchi, T; Kinoshita T et al. Randomised phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrectomy (ACTS-GC study). ASCO GI cancers Symp. San Francisco, USA; 2007.
268. Kindler, H; Niedzwiecki, D; Hollis D et al. A double-blind, placebo-controlled, randomised phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. ASCO GI cancers Symp. San Francisco, USA; 2007.
269. Saltz, L; Clarke, S; Diaz-Rubio E et al. Bevacizumab in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/N16966, a randomised phase III trial in the first-line treatment of metastatic colorectal cancer. ASCO GI cancers Symp. San Francisco, USA; 2007.
270. Cassidy, J; Clarke, S; Diaz-Rubio E et al. XELOX vs FOLFOX4: efficacy results from XELOX-1/N016966, a randomised phase III trial in first-line metastatic colorectal cancer. ASCO GI cancers Symp. San Francisco, USA; 2007.
271. Bennouna, J; Ducreux, M; Hebbar M et al. Preliminary efficacy findings from a randomized phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ASCO GI cancers Symp. San Francisco, USA; 2007.
272. Fuchs, C; Marshall, J; Mitchell E et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations ± celecoxib in mCRC: clinical data cut-off September 1, 2006. ASCO GI cancers Symp. San Francisco, USA; 2007.
273. Falcone, A; Andreuccetti, M; Orlandini C et al. Randomized phase III study of FOLFOXIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer: subgroup and multivariate analysis. ASCO GI cancers Symp. San Francisco, USA; 2007.
274. Van cutsem, E; Peeters, M; Siena S et al. A phase III randomized controlled trial of panitumumab in patients with metastatic colorectal cancer: subset analyses in elderly patients and in patients with poor performance status. ASCO GI cancers Symp. San Francisco, USA; 2007.
275. Porta, C; Ruff, P; Feld L et al. Results of a phase III, randomized controlled study, the largest ever completed in hepatocellular carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with nolatrexed or doxorubicin. ASCO GI cancers Symp. San Francisco, USA; 2006.
276. Falcone, A; Masi, G; Murr R et al. Biweekly irinotecan, oxaliplatin, and infusional 5FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer: results of a randomised, phase III trial by the Gruppo Oncologico Oncologico Nord Ovest (GONO). ASCO GI cancers Symp. San Francisco, USA; 2006.
277. Hurwitz, H; Zurlo, A; Kabbinavar F et al. Analysis of outcomes of patients with metastatic colorectal cancer treated with IFL with or without bevacizumab in a phase III clinical trial based on baseline risk. ASCO GI cancers Symp. San Francisco, USA; 2006.
278. Kubicka, S; Arkenau, H; Grothey A et al. Randomized trial of infusional 5-fluorouracil/folic acid plus oxaliplatin versus capecitabine plus oxaliplatin as first line treatment of metastatic colorectal carcinoma: final results of the safety and efficacy analysis. ASCO GI cancers Symp. San Francisco, USA; 2006.
279. Ashley, A; Alberts, S; Sargent D et al. Toxicity and efficacy of irinotecan/oxaliplatin as first-line treatment of metastatic colorectal cancer in N9741. ASCO GI cancers Symp. San Francisco, USA; 2006.
280. Schalhorn, A; Fischer von Weikersthal, L; Quietzsch D et al. Phase III trial of irinotecan plus oxaliplatin versus irinotecan plus 5-FU/folinic acid as first-line treatment of metastatic colorectal cancer: the FIRE-TRIAL. ASCO GI cancers Symp. San Francisco, USA;
281. Miyashiro, I; Furukawa, H; Sasako M et al. No survival benefit with adjuvant chemotherapy for serosa-positive gastric cancer: randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil in serosa-positive gastric cancer. Japan Clinical Oncology Group 9206-2. ASCO GI cancers Symp. San Francisco, USA; 2005.
282. Moore, M; Goldstein, D; Hamm J et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). ASCO GI cancers Symp. San Francisco, USA; 2005.
283. Maughan, T N colorectal group. Fluorouracil, oxaliplatin, CPT-11, use and sequencing in advanced colorectal cancer: the UK MRC FOCUS (CR08) trial. ASCO GI cancers Symp. San Francisco, USA; 2005.
284. De Gramont, A; Boni, C; Navarro M et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. ASCO GI cancers Symp. San Francisco, USA; 2005.
285. Giantonio, B; Catalano, P; Meropol N et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study (ECOG) E3200. ASCO GI cancers Symp. San Francisco, USA; 2005.
286. Van Cutsem E, Bodoky G, Kyung Roh J, Folprecht G, Park YS, van Laethem JL, et al. 3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC). ECCO. Barcelona, SPAIN; 2007. p. 235.
287. Koehne, C., Zaluski, J., Chung, C. R. Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial. World Congr. Gastrointest. Cancer. Barcelona, SPAIN; 2007.
288. Scheithauer W, Sobrero A, Lenz HJ, Maurel J, Lutz M, Middleton G, et al. 3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial. ECCO. Barcelona, SPAIN; 2007. p. 235–6.
289. Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff RA, Lloyd K, et al. 3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-. ECCO. Barcelona, SPAIN; 2007. p. 238.
290. Rothenberg M, Navarro M, Butts C, Bang Y, Cox J, Goel R, et al. 3012 ORAL Capecitabine + oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results. ECCO. Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD; 2007. p. 238–9.
291. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FLG, et al. 3015 ORAL Sequential vs. combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC). A Dutch Colorectal Cancer Group (DCCG) phase III study. ECCO. Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD; 2007. p. 239–40.
292. Comella P, Massidda B, Filippelli G, Farris A, Natale D, Maiorino L, et al. 3044 POSTER Capecitabine or Folinic acid/Fluorouracil i.v. bolus plus Eloxatin evaluation (COFFE trial) in metastatic colorectal carcinoma (MCRC): final results of the Southern Italy Cooperative Oncology Group (SICOG) phase III trial 0401. ECCO. Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD; 2007. p. 248–9.
293. Kang Y, Kang W, Shin D, Chen J, Xiong J, Wang J, et al. 3501 ORAL Capecitabine/cisplatin vs. continuous infusion of 5-FU/cisplatin as first-line therapy in patients (pts) with advanced gastric cancer (AGC): a randomised phase III trial. ECCO. Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD; 2007. p. 259.
294. Al-Batran SE, Hartmann JT, Probst S, Hofheinz R, Stoehlmacher J, Pauligk C, et al. 3502 ORAL Final results of a randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). ECCO. Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD; 2007. p. 259–60.
295. Langmuir VK, Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Kroll S, et al. 3505 ORAL Glufosfamide (GLU) in metastatic pancreatic adenocarcinoma previously treated with gemcitabine: Results of a Phase III trial. ECCO. Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD; 2007. p. 260–1.
296. Llovet J, Mazzaferro V, Ricci S, Hilgard P, Raoul J, Zeuzem S, et al. 3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma. ECCO. Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD; 2007. p. 261.
297. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). ASCO Meet. Abstr. 2007. p. LBA1.
298. Nordlinger B, Sorbye H, Collette L, Glimelius B, Poston GJ, Schlag PM, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. ASCO Meet. Abstr. 2007.
299. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. ASCO Meet. Abstr. 2007. p. 4000.
300. De Gramont A, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. ASCO Meet. Abstr. 2007. p. 4007.
301. Punt CJ, Koopman M, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study. ASCO Meet. Abstr. 2007. p. 4012.
302. Falcone A, Andreuccetti M, Brunetti I, Ricci S, Barbara C, Evangelista W, et al. Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC). ASCO Meet. Abstr. 2007. p. 4026.
303. Fuchs C, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: Updated efficacy data. ASCO Meet. Abstr. 2007. p. 4027.
304. Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. ASCO Meet. Abstr. 2007. p. 4028.
305. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). ASCO Meet. Abstr. 2007. p. 4029.
306. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). ASCO Meet. Abstr. 2007. p. 4030.
307. Rothenberg ML, Navarro M, Butts C, Bang Y, Cox J V, Goel R, et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). ASCO Meet. Abstr. 2007. p. 4031.
308. Kohne C, Bajetta E, Lin E, Valle JW, Van Cutsem E, Hecht JR, et al. Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. ASCO Meet. Abstr. 2007. p. 4033.
309. Schippinger W, Samonigg H, Greil R, Tschmelitsch J, Steger G, Jakesz R, et al. A prospective randomized phase III trial of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with stage II colon cancer. ASCO Meet. Abstr. 2007. p. 4052.
310. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, et al. N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC). ASCO Meet. Abstr. 2007. p. 4067.
311. Barrueco J, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients >65 years compared with those ? @ J K k x ˜ a
c
s
ÆÉRST‡ˆ?‘¾¿ÀÊËåæóëàëàØàØàØàØàëóàëàëɹ¥‘…¹‘vfVfRhÃ:hlVÅh
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.